{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:02:05Z","timestamp":1789066925705,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"am","delay-in-days":404,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.therap.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:10:10Z","timestamp":1650928210000},"page":"713-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Augmentation de l\u2019abus de m\u00e9thylph\u00e9nidate\u00a0: rep\u00e9rage et profils sur 13\u00a0ann\u00e9es"],"prefix":"10.1016","volume":"77","author":[{"given":"Cl\u00e9mence","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.03.006_bib0240","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2125.2009.03373.x","article-title":"Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996\u00a0and 2006","volume":"67","author":"Trip","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2013.09.001","article-title":"Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit\/hyperactivity disorder: United States, 2003\u20132011","volume":"53","author":"Visser","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.therap.2022.03.006_bib0250","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bcp.13000","article-title":"Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995\u20132015","volume":"82","author":"Renoux","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0255","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2022.03.006_bib0260","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1542\/peds.106.3.533","article-title":"Stimulant treatment in Maryland public schools","volume":"106","author":"Safer","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.therap.2022.03.006_bib0265","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jama.283.8.1025","article-title":"Trends in the prescribing of psychotropic medications to preschoolers","volume":"283","author":"Zito","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2022.03.006_bib0270","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5694\/j.1326-5377.2002.tb04948.x","article-title":"Licit psychostimulant consumption in Australia, 1984\u20132000: international and jurisdictional comparison","volume":"177","author":"Berbatis","year":"2002","journal-title":"Med J Aust"},{"key":"10.1016\/j.therap.2022.03.006_bib0275","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2515\/therapie\/2015012","article-title":"Example of an investigation of an \u201cemergent\u201d phenomenon in addiction vigilance: the case of methylphenidate","volume":"70","author":"Micallef","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.03.006_bib0280","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12887-015-0435-3","article-title":"Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study","volume":"15","author":"Boland","year":"2015","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.therap.2022.03.006_bib0285","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00228-012-1265-y","article-title":"The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective","volume":"68","author":"Potteg\u00e5rd","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0290","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00228-012-1344-0","article-title":"The use of medication against attention deficit\/hyperactivity disorder in Denmark: a drug use study from a patient perspective","volume":"69","author":"Potteg\u00e5rd","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0295","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00787-009-0075-y","article-title":"Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands","volume":"19","author":"Faber","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.therap.2022.03.006_bib0300","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-2004-813322","article-title":"The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions","volume":"66","author":"Schmidt-Troschke","year":"2004","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.therap.2022.03.006_bib0305","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00228-016-2125-y","article-title":"Use of drugs for ADHD among adults-a multinational study among 15.8\u00a0million adults in the Nordic countries","volume":"72","author":"Karlstad","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-0716-x","article-title":"Psychotropic drug use among 0\u201317\u00a0year olds during 2004\u20132014: a nationwide prescription database study","volume":"16","author":"Hartz","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.therap.2022.03.006_bib0315","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1600-0447.2010.01607.x","article-title":"Use of ADHD drugs in the Nordic countries: a population-based comparison study","volume":"123","author":"Zo\u00ebga","year":"2011","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.therap.2022.03.006_bib0320","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0091-3057(01)00464-6","article-title":"Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review","volume":"68","author":"Kollins","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.therap.2022.03.006_bib0325","series-title":"Arr\u00eat\u00e9 du 1er avril 2008\u00a0relatif \u00e0 la liste de soins ou traitements susceptibles de faire l\u2019objet de m\u00e9susage, d\u2019un usage d\u00e9tourn\u00e9 ou abusif","author":"Ministere de la sant\u00e9, de la jeunesse, des sports et de la vie associative","year":"2008"},{"key":"10.1016\/j.therap.2022.03.006_bib0330","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1328-2743(02)80016-5","article-title":"Illicit intravenous use of methylphenidate (Ritalin) tablets: A review of four cases","volume":"5","author":"Farquhar","year":"2002","journal-title":"Australian Emergency Nursing Journal"},{"key":"10.1016\/j.therap.2022.03.006_bib0335","first-page":"15","article-title":"\u00c9tude des pratiques d\u2019injection intraveineuse et autres d\u00e9tournements du m\u00e9thylph\u00e9nidate (r\u00e9gion Paca-Corse)","volume":"13","author":"Frauger","year":"2011","journal-title":"Le courrier des addictions"},{"key":"10.1016\/j.therap.2022.03.006_bib0340","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.therap.2018.02.005","article-title":"Pharmaceutical cognitive doping in students: A chimeric way to get-a-head?","volume":"73","author":"Carton","year":"2018","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2022.03.006_bib0345","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1054-139X(04)00067-9","article-title":"Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001","volume":"35","author":"McCabe","year":"2004","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.therap.2022.03.006_bib0350","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473710902020157","article-title":"Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences","volume":"2","author":"Bogle","year":"2009","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1016\/j.therap.2022.03.006_bib0355","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/chi.0b013e31815a56f1","article-title":"Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature","volume":"47","author":"Wilens","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.therap.2022.03.006_bib0360","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3200\/JACH.57.3.315-324","article-title":"Illicit use of prescription ADHD medications on a college campus: a multimethodological approach","volume":"57","author":"DeSantis","year":"2008","journal-title":"J Am Coll Health"},{"key":"10.1016\/j.therap.2022.03.006_bib0365","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1592\/phco.26.10.1501","article-title":"Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration","volume":"26","author":"Teter","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2022.03.006_bib0370","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1360-0443.2007.01758.x","article-title":"From attention-deficit\/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots","volume":"102","author":"Poulin","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2022.03.006_bib0375","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/fcp.12612","article-title":"Doctor shopping for methylphenidate as a proxy for misuse and potential abuse in the 67\u00a0million inhabitants in France","volume":"35","author":"Soeiro","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0380","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11587640-000000000-00000","article-title":"Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005\u00a0to 2008","volume":"25","author":"Frauger","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2022.03.006_bib0385","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.therap.2017.05.005","article-title":"Methylphenidate: gender trends in adult and pediatric populations over a 7year period","volume":"72","author":"Ehrhardt","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.03.006_bib0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000439273","article-title":"Patterns of methylphenidate use and assessment of its abuse among the general population and individuals with drug dependence","volume":"22","author":"Frauger","year":"2016","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2022.03.006_bib0395","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/ADM.0000000000000115","article-title":"Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: a descriptive population-based study","volume":"9","author":"Bjarnadottir","year":"2015","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2022.03.006_bib0400","series-title":"Collaborating Centre for drug statistics methodology. ATC\/DDD Index 2022","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.therap.2022.03.006_bib0405","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2515\/therapie:2003088","article-title":"D\u00e9tournement d\u2019usage du trihexyph\u00e9nidyle (Artane\u00ae, Parkinane\u00ae)\u202f: tendances r\u00e9centes","volume":"58","author":"Frauger","year":"2003","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.03.006_bib0410","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2515\/therapie:2006014","article-title":"D\u00e9tournement d\u2019usage du clonaz\u00e9pam (Rivotril\u00ae)\u202f: tendances r\u00e9centes","volume":"61","author":"Frauger","year":"2006","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.03.006_bib0415","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/fcp.12252","article-title":"Antidepressant adherence patterns in older patients: use of a clustering method on a prescription database","volume":"31","author":"Braunstein","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.006_bib0420","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drugalcdep.2010.06.016","article-title":"Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuse","volume":"113","author":"Pauly","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.03.006_bib0425","series-title":"M\u00e9thylph\u00e9nidate\u00a0: donn\u00e9es d\u2019utilisation et de s\u00e9curit\u00e9 d\u2019emploi en France","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2017"},{"key":"10.1016\/j.therap.2022.03.006_bib0430","series-title":"Avis de la commission de transparence. Ritaline 10mg\u00ae","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2002"},{"key":"10.1016\/j.therap.2022.03.006_bib0435","series-title":"Diagnostic and statistical manual of mental disorders (DSM)-5 (fifth edition)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.therap.2022.03.006_bib0440","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/1049909111427029","article-title":"Methylphenidate: established and expanding roles in symptom management","volume":"29","author":"Prommer","year":"2012","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.therap.2022.03.006_bib0445","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuropharm.2014.06.014","article-title":"The use of stimulant medications for non-core aspects of ADHD and in other disorders","volume":"87","author":"Sinita","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.therap.2022.03.006_bib0450","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.gaitpost.2014.10.022","article-title":"Gait and attentional performance in freezers under methylphenidate","volume":"41","author":"Delval","year":"2015","journal-title":"Gait Posture"},{"key":"10.1016\/j.therap.2022.03.006_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-012-0017-y","article-title":"Methylphenidate: a treatment for Parkinson's disease?","volume":"27","author":"Devos","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2022.03.006_bib0460","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.therap.2016.10.002","article-title":"Acute psychiatric symptoms during methylphenidate intravenous injections: A case report","volume":"72","author":"V\u00e9rit\u00e9","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.03.006_bib0465","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.drugalcdep.2017.04.028","article-title":"Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users","volume":"178","author":"Bjarnadottir","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.03.006_bib0235","series-title":"M\u00e9thylphenidate \u2013 Rappel des conditions de prescription, de d\u00e9livrance et de surveillance \u2013 Lettre aux professionnels de sant\u00e9","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2012"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572200066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572200066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:40Z","timestamp":1758567280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572200066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S004059572200066X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.03.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation de l\u2019abus de m\u00e9thylph\u00e9nidate\u00a0: rep\u00e9rage et profils sur 13\u00a0ann\u00e9es","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}